150 related articles for article (PubMed ID: 7323811)
21. Clinical testing of drugs for cancer in the United States and the Soviet Union.
Holland JF
Natl Cancer Inst Monogr; 1977 Mar; (45):261-2. PubMed ID: 927493
[No Abstract] [Full Text] [Related]
22. National Cancer Institute helps businesses cross 'the valley of death'.
Nair P
Nat Med; 2008 Aug; 14(8):795. PubMed ID: 18685581
[No Abstract] [Full Text] [Related]
23. Some historical and methodological developments in early clinical trials at the National Institutes of Health.
Greenhouse SW
Stat Med; 1990 Aug; 9(8):893-901; discussion 903-6. PubMed ID: 2218192
[TBL] [Abstract][Full Text] [Related]
24. When to test new drugs in chemosensitive tumors?
Stoter G
Ann Oncol; 1992 Feb; 3(2):102. PubMed ID: 1606079
[No Abstract] [Full Text] [Related]
25. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development.
Ansher SS; Scharf R;
Ann N Y Acad Sci; 2001 Dec; 949():333-40. PubMed ID: 11795372
[TBL] [Abstract][Full Text] [Related]
26. An agenda for clinical trials: clinical trials in the genomic era.
Simon RM
Clin Trials; 2004; 1(5):468-70. PubMed ID: 16279285
[No Abstract] [Full Text] [Related]
27. Drug regulation: quo vadis?
Goyan JE
JAMA; 1988 Nov; 260(20):3052-3. PubMed ID: 3184370
[No Abstract] [Full Text] [Related]
28. FDA introductory comments: clinical studies design and evaluation issues.
Woodcock J
Clin Trials; 2005; 2(4):273-5. PubMed ID: 16281424
[No Abstract] [Full Text] [Related]
29. Translation of cancer immunotherapies.
Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ
Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901
[No Abstract] [Full Text] [Related]
30. The National Cancer Institute: cancer drug discovery and development program.
Grever MR; Schepartz SA; Chabner BA
Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164
[TBL] [Abstract][Full Text] [Related]
31. Ethics and designs: laetrile trials as an example.
Newell GR; Ellison NM
Cancer Treat Rep; 1980; 64(2-3):363-5. PubMed ID: 6996807
[TBL] [Abstract][Full Text] [Related]
32. The advantages of using the clinical trials model for cancer control research.
La Chance PA; Vogt TM; Lichtenstein E
Prog Clin Biol Res; 1990; 339():383-9. PubMed ID: 2202997
[No Abstract] [Full Text] [Related]
33. The National Cancer Institute Cooperative Clinical Trials Program.
Weiss RB; Jacobs EM
CA Cancer J Clin; 1979; 29(5):287-90. PubMed ID: 113054
[No Abstract] [Full Text] [Related]
34. Shortcuts in drug evaluation.
Stolley PD; Lasky T
Clin Pharmacol Ther; 1992 Jul; 52(1):1-3. PubMed ID: 1623683
[No Abstract] [Full Text] [Related]
35. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
36. The conduct of phase I-II clinical trials in children with cancer.
Pratt CB
Med Pediatr Oncol; 1991; 19(4):304-9. PubMed ID: 2056975
[TBL] [Abstract][Full Text] [Related]
37. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
[No Abstract] [Full Text] [Related]
38. Clinical trials going to the dogs: canine program to study tumor treatment, biology.
Mack GS
J Natl Cancer Inst; 2006 Feb; 98(3):161-2. PubMed ID: 16449674
[No Abstract] [Full Text] [Related]
39. Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Carter SK; Slavik M
Natl Cancer Inst Monogr; 1977 Mar; (45):101-21. PubMed ID: 73134
[No Abstract] [Full Text] [Related]
40. [Focus on current trials of gene therapy in the United States].
Lehn P
Bull Cancer; 1995 Mar; 82(3):233. PubMed ID: 7655159
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
